[go: up one dir, main page]

GT200300108A - Derivados de benzoxazina y usos de los mismos - Google Patents

Derivados de benzoxazina y usos de los mismos

Info

Publication number
GT200300108A
GT200300108A GT200300108A GT200300108A GT200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A
Authority
GT
Guatemala
Prior art keywords
same
benzoxazine derivatives
compounds
neurotransmitter
modulators
Prior art date
Application number
GT200300108A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300108A publication Critical patent/GT200300108A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I EN LA QUE R1,R2,R3,R4,R5,R6,R7,R8,R9,Z1,P,Y,M,N, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON MODULADORES DEL NEUROTRANSMISOR 5HT6 POR LO QUE SON DE UTILIDAD EN UNA AMPLIA VARIEDAD DE CASOS TALES COMO TRASTORNOS DEL SNC, CIERTOS TRASTORNOS GASTROINTESTINALES.
GT200300108A 2002-05-13 2003-05-09 Derivados de benzoxazina y usos de los mismos GT200300108A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13

Publications (1)

Publication Number Publication Date
GT200300108A true GT200300108A (es) 2004-03-15

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300108A GT200300108A (es) 2002-05-13 2003-05-09 Derivados de benzoxazina y usos de los mismos

Country Status (36)

Country Link
US (4) US6867204B2 (es)
EP (1) EP1506179B1 (es)
JP (1) JP4307377B2 (es)
KR (1) KR100636475B1 (es)
CN (1) CN100429206C (es)
AR (1) AR039988A1 (es)
AT (1) ATE316523T1 (es)
AU (1) AU2003233231B2 (es)
BR (1) BRPI0310032B8 (es)
CA (1) CA2485136C (es)
DE (1) DE60303376T2 (es)
DK (1) DK1506179T3 (es)
EA (1) EA009982B1 (es)
EC (1) ECSP045420A (es)
EG (1) EG25683A (es)
ES (1) ES2256744T3 (es)
GT (1) GT200300108A (es)
HR (1) HRP20041030B1 (es)
IL (1) IL164928A0 (es)
JO (1) JO2413B1 (es)
MA (1) MA27118A1 (es)
MX (1) MXPA04011254A (es)
MY (1) MY139612A (es)
NO (1) NO329380B1 (es)
NZ (1) NZ536230A (es)
PA (1) PA8573501A1 (es)
PE (1) PE20040757A1 (es)
PL (1) PL211057B1 (es)
PT (1) PT1506179E (es)
RS (1) RS51042B (es)
TN (1) TNSN04225A1 (es)
TW (1) TWI258479B (es)
UA (1) UA76877C2 (es)
UY (1) UY27803A1 (es)
WO (1) WO2003095434A1 (es)
ZA (1) ZA200408783B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007956A1 (en) 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
NZ536230A (en) * 2002-05-13 2007-05-31 Hoffmann La Roche Benzoxazine derivatives as 5-hydroxytryptamine-6 (5-HT6) modulatory neurotransmitter in the brain
WO2004041792A1 (en) 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP4527730B2 (ja) 2003-12-09 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー ベンゾオキサジン誘導体及びその使用
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
NZ550441A (en) * 2004-05-05 2009-07-31 Hoffmann La Roche Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
DE602005026543D1 (de) * 2004-09-30 2011-04-07 Hoffmann La Roche Zusammensetzungen und verfahren zur behandlung kognitiver störungen
NZ553848A (en) * 2004-09-30 2010-01-29 Hoffmann La Roche Benzoxazine and quinoxaline derivatives and their use in treating diseases associated with the central nervous system
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
CA2935944A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
TR199902590T2 (xx) 1997-04-18 2000-06-21 Smithkline Beecham P.L.C. Birle�ik 5HT1A 5HT1B ve 5HT1D resept�r antagonist aktivitesi olan indol t�revleri.
TR200000073T2 (tr) 1997-07-11 2000-06-21 Smithkline Beecham P.L.C. 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi
EP1007523B9 (en) * 1997-07-25 2004-09-08 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
EP1089997A1 (en) * 1998-06-19 2001-04-11 H.Lundbeck A/S 4,5,6 and 7-indole and indoline derivatives, their preparation and use
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US7067513B1 (en) * 1999-08-23 2006-06-27 Solvay Pharmaceuticals B.V. Phenylpiperazines
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
NZ536230A (en) * 2002-05-13 2007-05-31 Hoffmann La Roche Benzoxazine derivatives as 5-hydroxytryptamine-6 (5-HT6) modulatory neurotransmitter in the brain

Also Published As

Publication number Publication date
TW200400188A (en) 2004-01-01
CA2485136C (en) 2011-12-20
EA009982B1 (ru) 2008-04-28
RS97004A (sr) 2006-10-27
BR0310032A (pt) 2005-02-15
US20030232825A1 (en) 2003-12-18
DE60303376D1 (de) 2006-04-13
UA76877C2 (uk) 2006-09-15
PL374019A1 (en) 2005-09-19
PA8573501A1 (es) 2003-12-10
CA2485136A1 (en) 2003-11-20
US8377931B2 (en) 2013-02-19
AU2003233231B2 (en) 2009-02-26
CN100429206C (zh) 2008-10-29
JP4307377B2 (ja) 2009-08-05
ES2256744T3 (es) 2006-07-16
KR20040106538A (ko) 2004-12-17
DE60303376T2 (de) 2006-11-16
EP1506179B1 (en) 2006-01-25
UY27803A1 (es) 2003-11-28
WO2003095434A1 (en) 2003-11-20
MA27118A1 (fr) 2004-12-20
MXPA04011254A (es) 2005-01-25
EG25683A (en) 2012-05-16
TNSN04225A1 (fr) 2007-03-12
BRPI0310032B8 (pt) 2021-05-25
AR039988A1 (es) 2005-03-09
AU2003233231A1 (en) 2003-11-11
HRP20041030B1 (hr) 2013-03-31
US20050130962A1 (en) 2005-06-16
CN1653054A (zh) 2005-08-10
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
PE20040757A1 (es) 2004-11-06
BRPI0310032B1 (pt) 2019-01-08
KR100636475B1 (ko) 2006-10-18
ECSP045420A (es) 2005-01-03
DK1506179T3 (da) 2006-06-06
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
ZA200408783B (en) 2005-12-28
HK1080846A1 (zh) 2006-05-04
NO329380B1 (no) 2010-10-04
NZ536230A (en) 2007-05-31
US6867204B2 (en) 2005-03-15
JP2005530774A (ja) 2005-10-13
JO2413B1 (en) 2007-11-11
US20130123251A1 (en) 2013-05-16
US20090325950A1 (en) 2009-12-31
EP1506179A1 (en) 2005-02-16
PT1506179E (pt) 2006-06-30
ATE316523T1 (de) 2006-02-15
RS51042B (sr) 2010-10-31
EA200401455A1 (ru) 2005-06-30
TWI258479B (en) 2006-07-21
PL211057B1 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
GT200300108A (es) Derivados de benzoxazina y usos de los mismos
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
GT200600159A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
GT200500183A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200300028A (es) Derivados iii de dihidrobenzodiacepina-2-ona
GT200300269A (es) Nuevos derivados fluoroglucosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
GT200300093A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
GT200400020A (es) Compuestos de triazol utiles en terapia
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
ECSP099728A (es) Compuestos amino-heterocíclicos
GT200300098A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
DOP2010000046A (es) Compuestos de biciclolactama sustituida
GT200300138A (es) Moduladores del receptor de glucocorticoides
GT200400032A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
CR10027A (es) Nuevos derivados de pirrol fusionado
CR8333A (es) Derivados biciclicos [3.1.0 ] como inhibidores del transportador de glicina
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
GT200200216A (es) Derivados del 3-azabiciclo [3.1.0] hexano
GT200200280A (es) Lactamas como antagonistas de taquiquininas
GT200400033A (es) Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos
GT200400117A (es) Derivados de imidazol
PA8768301A1 (es) Nuevos derivados tricíclicos, su procedimiento de preparación y las composiciones farmacéuticas que lo contienen